TY  - JOUR
AU  - Muchadeyi, Muchandifunga
AU  - Hao, Shuang
AU  - Hernandez Villafuerte, Karla Vanessa
AU  - Khan, Shah Alam
AU  - Becker, Nikolaus
AU  - Krilaviciute, Agne
AU  - Seibold, Petra
AU  - Gulati, Roman
AU  - Albers, Peter
AU  - Schlander, Michael
AU  - Clements, Mark
TI  - Cost effectiveness analysis of prostate cancer screening strategies in Germany: A microsimulation study.
JO  - Radiation oncology investigations
VL  - 157
IS  - 8
SN  - 1065-7541
CY  - New York, NY
PB  - Wiley Interscience
M1  - DKFZ-2025-01469
SP  - 1662-1679
PY  - 2025
N1  - #EA:C100# / 2025 Oct 15;157(8):1662-1679
AB  - Prostate cancer (PCa) represents a significant public health challenge in Germany, with increasing incidence and economic impact. This study assessed the cost-effectiveness of 10 screening strategies: prostate-specific antigen-based risk-adaptive screening (PSA-RAS), with or without magnetic resonance imaging (MRI), in men starting at age 45 or 50 and stopping at 60 or 70, digital rectal examination (DRE) for ages 45-75 years, and no screening. Using a well calibrated microsimulation model (Swedish Prostata) from a statutory health insurance perspective, lifetime outcomes were evaluated, including cancer incidence, mortality, overdiagnosis, biopsies, life-years, and quality-adjusted life-years (QALYs) discounted annually at 3
KW  - QALYs (Other)
KW  - cost‐effectiveness analysis (Other)
KW  - magnetic resonance imaging (Other)
KW  - organised screening (Other)
KW  - prostate cancer (Other)
KW  - prostate‐specific antigen (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40665795
DO  - DOI:10.1002/ijc.35513
UR  - https://inrepo02.dkfz.de/record/303022
ER  -